'Dallas Buyers' Club' for Hep C treatments under investigation

'Dallas Buyers' Club' for Hep C treatments under investigation
A "Dallas Buyers Club" of doctors and patients importing potentially life-saving Hepatitis C medication from countries like China is being investigated by the Therapeutic Goods Administration. Australians suffering Hepatitis C have been waiting for …
Read more here.

Study Looks at Clearance of Acute Hepatitis C in Cohort of Men
Among men who have sex with men and became acutely infected with hepatitis C, the virus spontaneously cleared in nearly half the cases with higher percentages among men who were noninjection drug users than men who inject drugs, according to a …
Read more here.

U.K. cost watchdog gives thumbs-up to Bristol-Myers' hep C drug
Bristol-Myers Squibb ($ BMY) got a go-ahead from the U.K.'s cost gatekeeper for its chronic hep C med Daklinza (daclatasvir), a win for the company as it finds its place in a fiercely contentious hep C market dominated by Gilead Sciences ($ GILD) and …
Read more here.

Singapore invites int'l experts to help review Hepatitis C mass infection
SINGAPORE, Oct. 17 (Xinhua) — Singapore government will invite international experts to help the current Independent Review Committee (IRC) look into the cause of mass infection of Hepatitis C at the Singapore General Hospital (SGH), Minister for …
Read more here.

Report: wide variance in Medicaid use of costly hepatitis C drug
A groundbreaking – but very expensive – new drug that cures many people with hepatitis C caused rapid and widespread increases in Medicaid spending in 2014, but with substantial variation across states, two doctors reported in a recent article in the …
Read more here.

Liver Enzymes Tell Tale in Hepatitis C Complications
The serum aminotransferase ratio — commonly used as a measurement of liver health — is associated with hepatosteatosis in patients with hepatitis C, according to Taiwanese researchers. The researchers, led by Ming-Shyan Lin, MD, Division of …
Read more here.

Merck plans to enter hep C market, take on Gilead & AbbVie with faster-acting
Merck's latest mid-stage hep C combo-drug study evaluated eight-week treatment regimens as the company attempts to gain a competitive advantage in a market dominated by Gilead and AbbVie. In the trial, the tested regimen wiped out hep C in more than …
Read more here.

Advera: AbbVie's Viekira Pak riskier than Gilead's Harvoni for hep C
AbbVie ($ ABBV) is facing bad news for its hep C powerhouse Viekira Pak as it dukes it out for market share with Gilead Sciences ($ GILD) in the hep C market. Healthcare informatics firm Advera Health Analytics looked at new side effect reports on hep C …
Read more here.


Leave a Reply